

COSTEM 2021 Scientific Program
all timing in CET

Thursday, October 21	
	Hall A
14:00-14:30	Place of allogeneic stem cell transplantation in multiple myeloma <i>Industry Meet the Expert (MTE) Session</i>
14:00-14:20 14:20-14:30	Place of allogeneic stem cell transplantation in MM: Nicolaus Kröger , Germany Q&A <i>This session is organized and funded by Riemser</i>
14:30-15:00	Extracorporeal photopheresis and the Biology of chronic GvHD <i>Industry Meet the Expert (MTE) Session</i>
14:30-14:50 14:50-15:00	The Biology of cGvHD: What's the mechanistic role of ECP in the current treatment landscape: Robert Zeiser , Germany Q&A <i>This session is organized and funded by Mallinckrodt-Therakos</i>
15:00-15:30	<i>Break – View the E-Posters – Visit Exhibition</i>
	Hall A
15:30-17:00	New chapters in the treatment of NHL and MM patients: CAR T <i>Industry Symposium</i> Chair: Nicolaus Kröger , Germany
15:30-16:00 16:00-16:30 16:30-17:00	Chapter 1: Targeting the immune system in MM – CAR T cell therapy and beyond (incl. Q&A): Stefan Knop , Germany Chapter 2: CAR T – Innovative therapy options for aggressive Lymphoma and CLL? (incl. Q&A): Lars Bullinger , Germany Chapter 3: Dos and Don'ts for CAR T cell therapies (incl. Q&A): Bertram Glaß , Germany <i>This session is organized and funded by Bristol Myers Squibb</i>

Friday, October 22

	Hall A		
09:00-10:45	Session 1: Opening Session		
09:00-09:15	Welcome Note Nicolaus Kröger , Germany; Arnon Nagler , Israel		
09:15-09:45	Controversy: Are CAR T cells the standard treatment for refractory DLBCL?		
09:15-09:30	Yes: Stephen Schuster , USA		
09:30-09:45	No: Mehdi Hamadani , USA		
09:45-10:15	Controversy: Is there a need for allogeneic SCT consolidation in ALL patients post CAR?		
09:45-10:00	Yes: Peihua Lu , China		
10:00-10:15	No: Michael Pulsipher , USA		
10:15-10:45	Panel discussion of both controversies Moderators: Nicolaus Kröger , Germany; Arnon Nagler , Israel		
10:45-11:00	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		Hall B
11:00-12:30	Session 2: Multiple myeloma I		11:00-12:30 Session 3: Acute myeloid leukemia
11:00-11:30	Controversy: Are CARs better for R/R Myeloma than antibodies?		11:00-11:30 Controversy: Maintenance post Allo in FLT3+ AML: Is sorafenib the new standard?
11:00-11:15	Yes: Noopur Raje , USA		11:00-11:15 Yes: Andreas Burchert , Germany
11:15-11:30	No: Hermann Einsele , Germany		11:15-11:30 No: Yi-Bin Chen , USA
11:30-12:00	Controversy: Still a role of allogeneic SCT as salvage treatment in MM?		11:30-12:00 Controversy: Is RIC sufficient in MRD neg. AML patients?
11:30-11:45	Yes: Gösta Gahrton , Sweden		11:30-11:45 Yes: Andreas Bacigalupo , Italy
11:45-12:00	No: Philippe Moreau , France		11:45-12:00 No: Charles Craddock , UK
12:00-12:30	Panel discussion of both controversies Moderators: Nicolaus Kröger , Germany; Hermann Einsele , Germany		12:00-12:30 Panel discussion of both controversies Moderators: Charles Craddock , UK; Arnon Nagler , Israel
12:30-13:00	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		
13:00-14:00	Paving the way to transplant in Acute Leukemias Industry Symposium		
13:00-13:05	Welcome and introduction: Matthias Stelljes , Germany		
13:05-13:35	Paving the way to transplant in r/r ALL for patients with high and with low disease burden: Matthias Stelljes , Germany / Alessandro Rambaldi , Italy		

13:35-13:55 13:55-14:00	AML therapy prior to transplant: Christoph Schmid , Germany Summary: Matthias Stelljes , Germany <i>This session is organized and funded by Pfizer</i>		
14:00-14:30	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		Hall B
14:30-16:00	Session 4: Haploidentical transplant	14:30-16:00	Session 5: Severe aplastic anemia and HLA-identical sibling SCT
14:30-15:15 14:30-14:45 14:45-15:00 15:00-15:15	Controversy: Is PTCy the better Haplo approach than ATG? Moderator: Arnon Nagler , Israel Yes: Leonido Luznik , USA No: He Huang , China Discussion	14:30-15:15 14:30-14:45 14:45-15:00 15:00-15:15	Controversy: Does introduction of eltrombopag change transplant indication for sAA? Moderator: Carlo Dufour , Italy Yes: Antonio Risitano , Italy No: Régis Peffault de Latour , France Discussion
15:15-16:00 15:15-15:30 15:30-15:45 15:45-16:00	Controversy: Is GVL stronger in Haplo than in MUD for AML? Moderator: Leonido Luznik , USA Yes: Nicolaus Kröger , Germany No: Arnon Nagler , Israel Discussion	15:15-16:00 15:15-15:30 15:30-15:45 15:45-16:00	Controversy: Do we need ATG/ATLG for GVHD prophylaxis in HLA-identical sibling transplant? Moderator: Francesca Bonifazi , Italy Yes: He Huang , China No: Robert Soiffer , USA Discussion
16:00-16:15	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		Hall B
16:15-17:45	Session 6: GVHD I	16:15-17:45	Session 7: Acute lymphocytic leukemia
16:15-16:45 16:15-16:30 16:30-16:45	Controversy: Is Ruxolitinib the new standard for second line therapy for cGVHD? Yes: Hildegard Greinix , Austria No: Steven Pavletic , USA	16:15-16:45 16:15-16:30 16:30-16:45	Controversy: How to bridge relapsed ALL to transplant? Blinatumomab: Renato Bassan , Italy Inotuzumab: Matthias Stelljes , Germany
16:45-17:15 16:45-17:00 17:00-17:15	Controversy: Should we perform gut decontamination pre-transplant? Yes: Ernst Holler , Germany No: Marcel van den Brink , USA	16:45-17:15 16:45-17:00 17:00-17:15	Controversy: Can allogeneic SCT in Ph+ ALL be avoided? Yes: Robin Foà , Italy No: Alessandro Rambaldi , Italy
17:15-17:45	Panel discussion of both controversies Moderators: Daniel Wolff , Germany; Steven Pavletic , USA	17:15-17:45	Panel discussion of both controversies Moderators: Dieter Hoelzer , Germany; Matthias Stelljes , Germany

Saturday, October 23

Hall A		Hall B	
09:30-11:00	Session 8: Myelodysplastic syndrome	09:30-11:00	Session 9: GVHD II
09:30-10:15	Controversy: Does mutation screening impact transplant decisions in MDS in 2020? Moderator: Ibrahim Yakoub-Agha , France	09:30-10:15	Controversy: Is PTCy the better GvHD prophylaxis than ATG in MUD? Moderator: Andreas Bacigalupo , Italy
09:30-09:45	Yes: Marie Robin , France	09:30-09:45	Yes: Mohamad Mohty , France
09:45-10:00	No: Avichai Shimoni , Israel	09:45-10:00	No: Francesca Bonifazi , Italy
10:00-10:15	Discussion	10:00-10:15	Discussion
10:15-11:00	Controversy: Should novel agents be used for induction prior to transplant in MDS EB1/2? Moderator: Avichai Shimoni , Israel	10:15-11:00	Controversy: Is Haplo the alternative to MUD in AA? Moderator: Régis Peffault de Latour , France
10:15-10:30	Yes: Uwe Platzbecker , Germany	10:15-10:30	Yes: Mahmoud Aljurf , Saudi Arabia
10:30-10:45	No: Ibrahim Yakoub-Agha , France	10:30-10:45	No: Carlo Dufour , Italy
10:45-11:00	Discussion	10:45-11:00	Discussion
11:00-11:15	<i>Break – View the E-Posters – Visit Exhibition</i>		
Hall A		Hall B	
11:15-12:45	Session 10: Myelofibrosis	11:15-12:45	Session 11: Multiple myeloma II
11:15-11:45	Controversy: 60y DIPSS intermediate I with <i>ASXL1</i> , <i>EZH2</i> , <i>SRSF2</i> Allo	11:15-11:45	Controversy: Is there a role for Auto in Amyloidosis in 2021?
11:15-11:30	Pro: Nicolaus Kröger , Germany	11:15-11:30	Yes: Stefan Schönland , Germany
11:30-11:45	Con: Francesco Passamonti , Italy	11:30-11:45	No: Giampaolo Merlini , Italy
11:45-12:15	Controversy: Early Allo in PMF patient responding to JAK2 inhibitor	11:45-12:15	Controversy: Is double Auto upfront in high-risk MM standard?
11:45-12:00	Pro: Juan Carlos Hernández-Boluda , Spain	11:45-12:00	Yes: Pieter Sonneveld , Netherlands
12:00-12:15	Con: Donal McLornan , UK	12:00-12:15	No: Sergio Giralt , USA
12:15-12:45	Panel discussion of both controversies Moderators: Marie Robin , France; Francesco Passamonti , Italy	12:15-12:45	Panel discussion of both controversies Moderators: Pieter Sonneveld , Netherlands; Hartmut Goldschmidt , Germany
12:45-13:15	<i>Break – View the E-Posters – Visit Exhibition</i>		
Hall A			
13:15-14:30	<u>CMV Prophylaxis – A Paradigm Shift in CMV Management?!</u> Industry Symposium		
	Introduction: Per Ljungman , Sweden		

	<p>What is the New Evidence in the Era of CMV Prophylaxis? Per Ljungman, Sweden When to start and how long to treat? – Experiences with CMV Prophylaxis: Guido Kobbe, Germany Real-world Evidence of CMV Prophylaxis – A Focus on CMV Blips and Prophylaxis Duration: Matthias Stelljes, Germany Discussion & Conclusion</p> <p><i>This session is organized and funded by MSD</i></p>		
14:30-14:45	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		Hall B
14:45-16:15	Session 12: Paediatrics	14:45-16:15	Session 13: Lymphoma
14:45-15:15 14:45-15:00 15:00-15:15	Controversy: Is TBI needed for allograft in ALL? Yes: Christina Peters , Austria No: Rupert Handgretinger , Germany	14:45-15:15 14:45-15:00 15:00-15:15	Controversy: Are monoclonal antibodies as effective as CAR-T in R/R DLBCL? Yes: Marion Subklewe , Germany No: Francis Ayuk , Germany
15:15-15:45 15:15-15:30 15:30-15:45	Controversy: Is haplo the alternative donor of choice for sickle cell anemia? Yes: Selim Corbacioglu , Germany No: Josu de la Fuente , UK	15:15-15:45 15:15-15:30 15:30-15:45	Controversy: Do CAR-T-cells have a role in treatment of CLL? Yes: David Porter , USA No: Ohad Benjamini , Israel
15:45-16:15	Panel discussion of both controversies Moderator: Selim Corbacioglu , Germany; Christina Peters , Austria	15:45-16:15	Panel discussion of both controversies Moderators: David Porter , USA; Robin Foà , Italy
16:15-16:30	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		Hall B
16:30-18:00	Session 14: COVID (I) and VOD	16:30-18:00	Session 15: Hodgkin lymphoma
16:30-17:15 16:30-16:45 16:45-17:00 17:00-17:15	Controversy: Are patients after resolution of COVID-19 at higher risk after allogeneic SCT? Moderator: Alessandro Rambaldi , Italy Yes: Per Ljungman , Sweden No: Malgorzata Mikulska , Italy Discussion	16:30-17:15 16:30-16:45 16:45-17:00 17:00-17:15	Controversy: Is there a role for Allo in HL? Moderator: TBA Yes: Anna Sureda , Spain No: Nico Gagelmann , Germany Discussion
17:15-18:00 17:15-17:30 17:30-17:45	Controversy: Do we need new diagnostic criteria for VOD? Moderator: Antonio Pagliuca , UK Yes: Selim Corbacioglu , Germany No: Rafael Duarte , Spain Discussion	17:15-18:00 17:15-17:30 17:30-17:45	Controversy: Is Haplo the donor of choice in relapsing HL for allogeneic SCT? Moderator: Michael Bishop , USA Yes: Didier Blaise , France No: Ali Bazarbachi , Lebanon

17:45-18:00		17:45-18:00	Discussion
18:00-18:10	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		
18:10-18:30	COSTEM 2021 Poster Award Ceremony Awards presented by: Nicolaus Kröger , Germany; Arnon Nagler , Israel		

Sunday, October 24			
	Hall A		
09:30-11:00	Session 16: Cellular therapies I		
09:30-10:00	Controversy: Are dual CARs more effective?		
09:30-09:45	Yes: Nirali Shah , USA		
09:45-10:00	No: Michael Bishop , USA		
10:00-10:30	Controversy: Are NK-CAR cells as effective as CAR-T-cells?		
10:00-10:15	Yes: Ulrike Köhl , Germany		
10:15-10:30	No: Michael Hudecek , Germany		
10:30-11:00	Panel discussion of both controversies Moderators: Michael Hudecek , Germany; Chiara Bonini , Italy		
11:00-11:15	<i>Break – View the E-Posters – Visit Exhibition</i>		
	Hall A		
11:15-12:45	Session 17: Cellular therapies II and COVID (II)		
11:15-12:00	Controversy: Are TCR engineering-based cell therapies the next buster in T-cell based immunotherapy?		
	Moderator: Michael Bishop , USA		
11:15-11:30	Yes: Chiara Bonini , Italy		
11:30-11:45	No: Christian Chabannon , France		
11:45-12:00	Discussion		
12:00-12:45	Controversy: Is early COVID vaccination after allogeneic stem cell transplantation effective?		
	Moderator: Per Ljungman , Sweden		
12:00-12:15	Yes: Rafael de la Cámara , Spain		
12:15-12:30	No: Malgorzata Mikulska , Italy		
12:30-12:45	Discussion		
12:45-13:00	Closing Remarks		

	Nicolaus Kröger , Germany; Arnon Nagler , Israel
--	--